Please use this identifier to cite or link to this item:
|Title:||The dearth of new antibiotic development: why we should be worried and what we can do about it.||Austin Authors:||Charles, Patrick G P ;Grayson, M Lindsay||Affiliation:||Infectious Diseases Department, Austin Health, Heidelberg, VIC.||Issue Date:||15-Nov-2004||Publication information:||Medical Journal of Australia; 181(10): 549-53||Abstract:||The emergence and spread of multidrug-resistant pathogens has increased substantially over the past 20 years. Over the same period, the development of new antibiotics has decreased alarmingly, with many pharmaceutical companies pulling out of antibiotic research in favour of developing "lifestyle" drugs. Reasons given for withdrawing from antibiotic development include poor "net present value" status of antibiotics, changes in regulations requiring larger drug trials and prolonged post-marketing surveillance, clinical preference for narrow-spectrum rather than broad-spectrum agents, and high new-drug purchase costs. Major improvements in infection control in Australia are needed to prevent further spread of resistant clones, buying some time to develop urgently needed new antibiotic agents. Perpetuating a culture of "pharma bashing" will simply lead to more pharmaceutical companies withdrawing from the market. A change in the health and research culture is needed to improve cooperation between public, academic and private sectors.||Gov't Doc #:||15540967||URI:||http://ahro.austin.org.au/austinjspui/handle/1/9829||URL:||https://pubmed.ncbi.nlm.nih.gov/15540967||Type:||Journal Article||Subjects:||Anti-Bacterial Agents.therapeutic use
Drug and Narcotic Control
Product Surveillance, Postmarketing
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 30, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.